RESEARCH MONOGRAPH · KDC-MN-002

BPC-157

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

72/100

Real signal under the hype. Sourcing is rock solid, evidence is partial

Look, BPC-157 is the peptide everyone wants to be true. The mechanism story is honestly kind of messy. The BPC name comes from a stomach-derived parent fragment that nobody isolated cleanly, and the human evidence is mostly anecdote plus a handful of small Croatian papers from the Sikiric group at Zagreb that nobody else has repeated at the scale you'd want.

But the preclinical literature is unusually consistent. Tendon, ligament, gut lining, eye, neuro injury models, you see the same effect direction over and over again across decades and across rat strains. So there's something real happening here, the question is whether it translates to humans at sub-mg subcutaneous doses, and honestly we dont know yet. There are a couple of small clinical trials currently running on knee and Achilles tendinopathy, those will tell us a lot.

Mechanism-wise, the leading story is upregulation of VEGFR2 and nitric oxide signaling, plus modulation of the dopaminergic and serotonergic systems peripherally. None of that has been pinned down with the kind of receptor pharmacology you'd want.

Sourcing-wise it's a forgiving compound. Short sequence (15 residues), HPLC validation is straightforward, vendor variability between reputable suppliers stays pretty tight. Reconstitution is normal bacteriostatic-water territory and the peptide is stable enough to survive lab handling without much drama.

What we don't like is how the internet talks about it. People treat BPC-157 like aspirin for tissue injury and thats just not where the evidence sits. Treat it like the early-stage research tool it actually is, watch what comes out of the clinical trials currently running, and don't oversell it to yourself. The Sikiric group is genuinely productive but the lack of independent replication at scale is the central scientific problem here, not a footnote.

Worth keeping in the rotation as a research target? yeah, honestly. The signal is too consistent across labs and models to ignore. Just temper expectations until human data lands.

Evidence: 62
Mechanism: 60
Reliability: 75
Safety: 80
Sourcing: 85
Value: 72
Signal: 78
Staying power: 65

Plain-language summary Intrigue 78 / 100

BPC-157 is a small protein fragment originally isolated from human stomach acid. Researchers found that it speeds up healing of injured tendons, ligaments, muscles, and gut tissue in animal studies. It is one of the most popular peptides in injury recovery research, though human clinical trials are limited. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Pentadecapeptide (gastric BPC fragment)

A 15-amino-acid sequence derived from a gastric protective protein, broadly studied in tendon, ligament, vascular, and gut repair models.

Abstract

BPC-157, formally pentadecapeptide BPC 157 (Body Protection Compound 157), is a 15-residue partial sequence isolated from a larger gastric protective protein found in human gastric juice. The sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (CAS 137525-51-0; molecular formula C62H98N16O22; molecular weight 1419.55) was originally characterized in the 1990s by the Sikiric group at the University of Zagreb, who have authored the majority of the published preclinical record. Reported activities span tendon and ligament healing in transection models, vascular reorganization through nitric oxide synthase modulation and VEGF receptor 2 engagement, gastrointestinal mucosal protection, dopaminergic system modulation, and GH receptor crosstalk. Routes studied include intraperitoneal, intramuscular, subcutaneous, oral, and topical administration in rodent models; oral bioavailability is unusual for a peptide of this length and is attributed to the parent compound's evolutionary role in the gut. Human pharmacokinetic data are sparse; one published Phase 1 single-ascending-dose study has been reported. BPC-157 is not approved by any regulatory authority for human or veterinary use. The literature base is dominated by a single research group, which is the principal limitation on the strength of the evidence; independent replications of the most-cited findings are limited but growing. This monograph reviews the chemistry, mechanism, pharmacokinetics, dosing literature, sourcing risks, and reconstitution practice for in vitro and in vivo investigative work.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-002

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

Acquire BPC-157 from the catalog

View BPC-157 →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

BPC-157

Abstract

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Read the full monograph

Adjacent monographs